Suchergebnisse - Subhashis Banerjee

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis:... von Shinichi Imafuku, Yukari Okubo, Yayoi Tada, Mamitaro Ohtsuki, Elizabeth Colston, Andrew Napoli, Yanqiu Shao, Subhashis Banerjee, Akimichi Morita

Volltext

Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO ‐1, PSO ‐4, and LTE trials von Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Yukari Okubo, Katsuyoshi Habiro, Katsuki Tsuritani, Subhashis Banerjee, Kim Hoyt, Renata M. Kisa, Mamitaro Ohtsuki

Volltext

Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient‐reported outcomes in the POETYK PSO‐4 study von Yayoi Tada, April W. Armstrong, Shinichi Imafuku, Yukari Okubo, Akimichi Morita, Yichen Zhong, Joe Zhuo, Brandon Becker, Andrew Napoli, Subhashis Banerjee, Mamitaro Ohtsuki

Volltext

Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials von April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Akimichi Morita, Carle Paul, Kim A. Papp, Matthew J. Colombo, Julie Scotto, John Vaile, Joe Zhuo, Eleni Vritzali, Victoria Berger, Georgene Schroeder, Subhashis Banerjee, Diamant Thaçi, Bruce Strober

Volltext